Garry Nolan - 21 May 2021 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Director
Signature: /s/ Garry Nolan, by Joseph Driscoll, as Attorney-in-Fact
Issuer symbol: AKYA
Transactions as of: 21 May 2021
Transactions value $: $0
Form type: 4
Filing time: 25 May 2021, 21:53:10 UTC
Next filing: 13 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AKYA	Common Stock						680,084	21 May 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Stock Option (Right to Buy	Award	$0	+16,860		$0	16,860	21 May 2021	Common Stock	16,860	$21.95	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) May 21, 2022, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.